Fluoroquinolone and other antimicriobial resistance in invasive pneumococci, Hong Kong, 1995-2001

Emerging Infectious Diseases

Volumn 10, Issue 7, 2004, Pages 1250-1257

  Ho, Pak Leung ^a   Que, Tak Lun ^b   Chiu, Susan S ^a   Yung, Raymond W H ^c   Ng, Tak Keung ^d   Tsang, Dominic N C ^e   Seto, Wing Hong ^a   Lau, Yu Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

^c PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFEPIME; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CONJUGATION; DISEASE PREDISPOSITION; HONG KONG; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ONSET AGE; PREVALENCE; SEROTYPE; STREPTOCOCCUS INFECTION; VACCINATION; ADOLESCENT; ADULT; CHILD; CLASSIFICATION; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HONG KONG; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 3042703738     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1007.030612     Document Type: Article

References (32)

1. Ho PL, Cheng VCC. Epidemiology and mechanisms of resistance. In: Ronald AR, Low DE, editors. Milestones in drug therapy: fluoroquinolone antibiotics. Berlin: Birkhauser; 2003. p. 49-72.
2. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341:233-9.
3. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother. 1999;43:1310-3.
4. Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Seto WH, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001;48:659-65.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. 2001. M100-S11. Wayne (PA): The Committee; 2001.
6. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med. 1976;43:699-709.
7. Coffey TJ, Dowson CG, Daniels M, Zhou J, Martin C, Spratt BG, et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol. 1991;5:2255-60.
8. Ho PL, Yam WC, Que TL, Tsang DNC, Seto WH, Ng TK, et al. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J Antimicrob Chemother. 2001;47:655-8.
9. Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, Cheng VCC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701-7.
10. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-24.
11. Sahm DF, Peterson DE, Critchley IA, Thornsberry C. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother. 2000;44:2521-4.
12. Sahm DF, Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry C, et al.. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother. 2001;45:1037-42.
13. Jorgensen JH, Beall B, Hadler J, Harrison LH, Bennett N, Craig A, et al. Invasive disease due to fluoroquinolone-resistant pneumococcus in six surveillance areas, 1998-2000. In: The Third International Symposium on Pneumococci and Pneumococcal Diseases. 5-8 May, 2002. Anchorage, Alaska, USA. Washington: American Society for Microbiology; 2002. Poster 68A.
14. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother. 2002;49:173-6.
15. Geore RC, Harrison T, Sheppard C, Johnson A, Walker R, Harnett S. Resistance pneumococcal clones and quinolones: an emerging problem. Program and abstracts book: 3rd international symposium on pneumococci and pneumococcal diseases. May 5-8, 2002. Washington: American Society for Microbiology; 2002. p. 26.
16. Alou L, Ramirez M, Garcia-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: Clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother. 2001;45:2955-7.
17. Ip M, Lyon DJ, Yung RW, Chan C, Cheng AF. Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. J Clin Microbiol. 1999;37:2834-9.
18. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Luh KT. Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J Clin Microbiol. 1999;37:897-901.
19. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286:1857-62.
20. Reinert RR, Al Lahham A, Lemperle M, Tenholte C, Briefs C, Haupts S, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother. 2002;49:61-8.
21. Weiss K, Guilbault C, Cortes L, Restieri C, Low DE. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother. 2002;50:403-6.
22. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis. 2002;35:565-9.
23. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa-de-Echaguen A, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35:556-64.
24. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-95.
25. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
26. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180:1171-6.
27. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927-36.
28. Givon-Lavi N, Fraser D, Porat N, Dagan R. Spread of Streptococcus pneumoniae and antibiotic-resistant S. pneumoniae from day-care center attendees to their younger siblings. J Infect Dis. 2002;186:1608-14.
29. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-55.
30. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
31. Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine. 2003;21:3906-11.
32. Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721-7.